Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04948619 · ClinicalTrials.gov registry record · Phase 2
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
A Phase 2 study of Pediatric Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04948619: Recruiting Phase 2 study of Pediatric Cancer, sponsored by Wake Forest University Health Sciences.
NCT04948619 is a Phase 2 study of Pediatric Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 64 participants, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04948619, a Phase 2 study of Pediatric Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superior for regaining immunity against potentially serious infections in survivors.
Primary Outcome
To compare single booster vaccination (Arm A) to full revaccination (Arm B) in terms of immune response at 24 months post cancer directed systemic therapy in pediatric subjects who have received cancer directed systemic therapy for any malignancy.
Conditions Studied
Interventions
- BIOLOGICAL Vaccine
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2030-10 |
| Phase | Phase 2 |
What NCT04948619 shows while recruiting
NCT04948619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Vaccine is the first listed.
NCT04948619 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04948619 about?
NCT04948619 is a clinical study titled "Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients". Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applic...
What is the current status of trial NCT04948619?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2022-08-08. Estimated completion is 2030-10.
What conditions does trial NCT04948619 study?
This clinical trial studies the following conditions: Pediatric Cancer.
What interventions are being tested in trial NCT04948619?
The interventions under investigation include: Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04948619?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04948619 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04948619's enrollment target sits among peer trials
64 23rd of 51 higher than 28 of 51 other Pediatric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
RECRUITING · Phase 2
-
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
-
Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI